1,2-Dibenzamidobenzene inhibitors of human factor Xa.
High-throughput screening of a combinatorial library of diamidophenols yielded lead compounds with the ability to inhibit human factor Xa (fXa) at micromolar concentrations (e.g. compound 4, fXa apparent K(ass) = 0.64 x 10(6) L/mol). SAR studies in this novel structural series of fXa inhibitors showed that the phenolic hydroxyl group was not essential for activity. The best activity was found in substituted 1,2-dibenzamidobenzenes in which the phenyl group of one benzoyl group (A-ring) was substituted in the 4-position with relatively small lipophilic or polarizable groups such as methoxy, vinyl, or chloro and the phenyl group of the other benzoyl group (B-ring) was substituted in the 4-position with larger lipophilic groups such as tert-butyl or dimethylamino. The central phenyl ring (C-ring) tolerated a wide variety of substituents, but methoxy, methanesulfonamido, hydroxyl, and carboxyl substitution produced slightly higher levels of activity than other substituents when present in combination with favorable B-ring substitution. Methylation of the amide nitrogen atoms was found to greatly decrease activity. Compound 12 is the highest affinity fXa inhibitor in this group of compounds, having fXa apparent K(ass) = 25.5 x 10(6) L/mol, about 40x more active than the original lead. This lead series does not show potent inhibition of human thrombin. A model for the binding of these ligands to the fXa active site is proposed. The model is consistent with the observed SAR and can serve to guide future SAR studies.
Herron
D K
DK
Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, Indiana 46285, USA. dkherron@lilly.com
Goodson
T
T
Wiley
M R
MR
Weir
L C
LC
Kyle
J A
JA
Yee
Y K
YK
Tebbe
A L
AL
Tinsley
J M
JM
Mendel
D
D
Masters
J J
JJ
Franciskovich
J B
JB
Sawyer
J S
JS
Beight
D W
DW
Ratz
A M
AM
Milot
G
G
Hall
S E
SE
Klimkowski
V J
VJ
Wikel
J H
JH
Eastwood
B J
BJ
Towner
R D
RD
Gifford-Moore
D S
DS
Craft
T J
TJ
Smith
G F
GF
D000925:Anticoagulants / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism; D001665:Binding Sites; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism; D015951:Factor Xa / Q000737:chemistry / Q000378:metabolism; D065427:Factor Xa Inhibitors; D006801:Humans; D008958:Models, Molecular; D010655:Phenylenediamines / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D015842:Serine Proteinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000925:Anticoagulants; D004791:Enzyme Inhibitors; D065427:Factor Xa Inhibitors; C406226:N(2)-(4-(dimethylamino)benzoyl)-4-hydroxy-N(1)-(4-methoxybenzoyl)-1,2-benzenediamine; D010655:Phenylenediamines; D015842:Serine Proteinase Inhibitors; D013449:Sulfonamides; D013917:Thrombin; D015951:Factor Xa